TAO Synergies Inc.

NASDAQ: TAOX · Healthcare · Biotechnology

PublicHQ New York, CIK 0001571934Reports USD

#961 of 1,394 Healthcare companies by revenue

EA Score

28D

FH 39DQ 12GM —SS 21

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$687.8k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$28.7M

Employees

Market cap

$12.0M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$299.1k$299.1k2025

Net income-$28.7M-$28.7M2025

Operating income-$9.0M-$9.0M2025

Total assets$25.8M$25.8M2025

Liabilities$3.9M$3.9M2025

Equity$21.1M$21.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

TAO Synergies Inc. booked $299.1k in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -9609.2% net margin.

Peers · Healthcare

Exicure, Inc.31D Regional Health Properties, Inc.67B VolitionRX Ltd38D Kiora Pharmaceuticals, Inc.52D

Key facts

CEOJoshua N. Silverman

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York, null

ExchangeNASDAQ: TAOX

Employees4

IPO date2025-07-02

Latest filings

10-Q2026-05-13 10-K2026-03-31 8-K2025-12-19 DEF 14A2025-11-17 10-Q2025-11-14 8-K2025-10-14 8-K2025-08-29 10-Q2025-08-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.

TAO Synergies Inc.

Financials — latest annual

Revenue by segment

TAO Synergies Inc.